全文获取类型
收费全文 | 3557087篇 |
免费 | 269244篇 |
国内免费 | 8662篇 |
专业分类
耳鼻咽喉 | 48948篇 |
儿科学 | 118329篇 |
妇产科学 | 99844篇 |
基础医学 | 499844篇 |
口腔科学 | 102151篇 |
临床医学 | 323571篇 |
内科学 | 691317篇 |
皮肤病学 | 82601篇 |
神经病学 | 291853篇 |
特种医学 | 139419篇 |
外国民族医学 | 1130篇 |
外科学 | 534865篇 |
综合类 | 79186篇 |
现状与发展 | 6篇 |
一般理论 | 1403篇 |
预防医学 | 276958篇 |
眼科学 | 81491篇 |
药学 | 264565篇 |
9篇 | |
中国医学 | 6739篇 |
肿瘤学 | 190764篇 |
出版年
2018年 | 37669篇 |
2017年 | 29191篇 |
2016年 | 33569篇 |
2015年 | 38191篇 |
2014年 | 52535篇 |
2013年 | 79616篇 |
2012年 | 105891篇 |
2011年 | 111873篇 |
2010年 | 67323篇 |
2009年 | 64506篇 |
2008年 | 105333篇 |
2007年 | 111636篇 |
2006年 | 113481篇 |
2005年 | 109335篇 |
2004年 | 106118篇 |
2003年 | 101970篇 |
2002年 | 98802篇 |
2001年 | 167192篇 |
2000年 | 171681篇 |
1999年 | 144688篇 |
1998年 | 39753篇 |
1997年 | 35231篇 |
1996年 | 35145篇 |
1995年 | 36332篇 |
1994年 | 33601篇 |
1993年 | 31581篇 |
1992年 | 115920篇 |
1991年 | 112623篇 |
1990年 | 109316篇 |
1989年 | 105889篇 |
1988年 | 97618篇 |
1987年 | 95937篇 |
1986年 | 90733篇 |
1985年 | 86997篇 |
1984年 | 65079篇 |
1983年 | 55569篇 |
1982年 | 32860篇 |
1981年 | 29526篇 |
1979年 | 59619篇 |
1978年 | 41779篇 |
1977年 | 35430篇 |
1976年 | 33078篇 |
1975年 | 35269篇 |
1974年 | 42295篇 |
1973年 | 40342篇 |
1972年 | 37728篇 |
1971年 | 35241篇 |
1970年 | 32447篇 |
1969年 | 31039篇 |
1968年 | 28391篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
Hendrik Kröning Thomas Göhler Thomas Decker Marc Grundeis Georgi Kojouharoff Jörg Lipke Dieter Semsek Enno Moorahrend Annette Sauer Harald-Robert Bruch Rüdiger Liersch Arnd Nusch Ursula Vehling-Kaiser Manfred Welslau Ralf Grunewald Hanns-Detlev Harich Marcel Stephany Jens Uhlig Rebecca de Buhr Melanie Frank Cathrin Hogrefe Norbert Marschner Karin Potthoff Frank Hartmann Timo Reisländer Ingo Schwaner 《International journal of cancer. Journal international du cancer》2023,153(6):1227-1240
The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) in a real-world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial. Primary endpoint was overall survival (OS). Secondary objectives included progression-free survival (PFS), safety, and quality of life (QoL). Subgroups comprised patients with good (<3 metastatic sites at inclusion, ≥18 months from diagnosis of first metastasis to inclusion) or poor (remaining patients) prognostic characteristics (GPC/PPC). GPC without liver metastases was considered best prognostic characteristics (BPC). In total, 307 eligible patients (pretreated or not suitable for other available therapies) were treated with FTD/TPI. Overall, median [95%-CI] OS was 7.4 months [6.4-8.6], median PFS was 2.9 months [2.8-3.3]. In BPC (n = 65) and GPC (n = 176) compared to PPC (n = 124) subgroup, median OS (13.3 [9.1-17.6] vs 8.9 [7.6-9.8] vs 5.1 [4.4-7.0] months) and median PFS (4.0 [3.3-5.3] vs 3.4 [3.0-3.7] vs 2.6 [2.4-2.8] months) were longer. Patient-reported QoL, assessed by validated questionnaires (EQ-5D-5L, PRO-CTCAE), was stable throughout FTD/TPI treatment. Predominant FTD/TPI-related adverse events of grades 3 or 4 were neutropenia (13.0%), leukopenia (7.5%), and anemia (5.2%). Altogether, palliative FTD/TPI therapy in patients with pretreated mCRC was associated with prolonged survival, delayed progression, maintained health-related QoL, and manageable toxicity. Low metastatic burden and indolent disease were favorable prognostic factors for survival. TACTIC confirms the effectiveness and safety of FTD/TPI, highlighting its value in routine clinical practice. 相似文献
72.
Stefaniuk Catherine M. Schlegelmilch June Meyerson Howard J. Harding Clifford V. Maitta Robert W. 《Journal of thrombosis and thrombolysis》2022,53(4):950-953
Journal of Thrombosis and Thrombolysis - Over the last few years data from our group have indicated that α-synuclein is important in development of immune cells as well as potentially... 相似文献
73.
Schneider Ralph Dettmer Marius Peters Nora Lamdark Tenzin Luedi Markus M. Adamina Michel Doll Dietrich 《European Surgery》2022,54(2):117-125
European Surgery - Treatment of pilonidal sinus disease (PSD) requires a tailored approach. A national guideline was published in 2014. The current status of surgical PSD therapy... 相似文献
74.
Troppmair Teresa Egger J. Krösbacher A. Zanvettor A. Schinnerl A. Neumayr A. Baubin M. 《Der Anaesthesist》2022,71(4):272-280
Die Anaesthesiologie - Die Qualität eines Rettungssystems zeichnet sich auch durch den effizienten Einsatz seiner personellen und Fahrzeugressourcen aus. So können im berechtigten Fall... 相似文献
75.
Die Anaesthesiologie - Eine junge Patientin erleidet während der Anlage einer axillären Plexusblockade einen generalisierten Krampfanfall. Die Mechanismen, im Wesentlichen die vermutlich... 相似文献
76.
77.
Juan Carlos Casado-Morente Elena Mora Rivas Carlos O’Connor Reina Soledad Angulo Serrano Estefanía Díaz-Fresno Isabel Sandoval-Menéndez Antonio Becerra M. Jesús Lucio Faustino Núñez-Batalla 《Acta otorrinolaringologica espanola》2021,72(1):21-26
ObjectiveThe aim of this study was to create and validate an abbreviated version of the Spanish Transsexual Voice Questionnaire for Male-to-Female Transsexuals (SvTVQMtF).SettingThe study was conducted by two referral hospitals for voice feminization surgery and by a university department of psychology and speech therapy, all in Spain.Subjects and methodsWe prospectively studied 51 male-to-female transsexuals who underwent voice feminization surgery between January 2017 and December 2018. The SvTVQMtF was completed before and after surgery, and the 10 items with the greatest variation were selected by clinical consensus of an expert panel to develop the short version of the SvTVQMtF (SvTVQMtF-10). The correlation between the total score and the score for each item on the SvTVQMtF and the SvTVQMtF-10 was studied. The internal consistency of the SvTVQMtF-10 was analysed.ResultsGood correlation (Pearson coefficient above .90) was found between the two questionnaires. A significant correlation was found between the total SvTVQMtF-10 score and the score for each item. A significant negative correlation was found between the SvTVQMtF and fundamental frequency after voice feminization surgery. Cronbach's α was .79.ConclusionThe SvTVQMtF-10 is a valid short version of the SvTVQMtF and can be used to quantify voice-related quality of life in MtF transsexuals. 相似文献
78.
79.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
80.
- Children with cancer receive many medications outside the hospital administered by their caregivers.
- The study by Walsh et al. shows the number and types of medication errors in these patients. The study includes data from three different centers.
- Importantly, the study shows the types of errors that cause harm. The authors describe how the harmful errors can be prevented.
- We suggest ways these results can be used to identify which patients and families will benefit from additional attention. Providing more help at clinic and in the home may help prevent harmful medication errors in children with cancer.